Enalapril Shortage: What Providers and Prescribers Need to Know in 2026

Enalapril maleate remains one of the most evidence-based ACE inhibitors in clinical practice, with FDA approval for hypertension, symptomatic congestive heart failure, and asymptomatic left ventricular dysfunction (EF ≤35%). As of early 2026, enalapril oral tablets are not on the FDA's active drug shortage list. However, pharmacy-level supply disruptions continue to affect patients across multiple regions, and providers are increasingly fielding calls from patients who cannot fill their prescriptions.

This clinical briefing summarizes the current supply landscape, prescribing implications, and practical resources for providers managing patients on enalapril.

Current Supply Status (2026)

Oral tablets (2.5 mg, 5 mg, 10 mg, 20 mg): Not on the FDA drug shortage list as of early 2026. Generally available through standard distribution channels, but localized stock-outs persist.

Enalaprilat IV (1.25 mg/mL injection): Has experienced periodic shortage listings. Providers in inpatient and ICU settings should check current ASHP shortage updates for available alternatives.

Epaned (oral solution, 1 mg/mL): Brand-only liquid formulation. Not covered by most Medicare or insurance plans; availability may vary.

Why Pharmacy-Level Stock-Outs Occur Without an Official Shortage

The FDA shortage designation has a defined threshold — it typically requires a meaningful impact on the national supply. Localized pharmacy-level disruptions can cause significant patient impact without triggering a formal shortage declaration. Drivers include:

Thin manufacturing margins on generic drugs limiting safety stock capacity

Distributor allocation caps that prevent pharmacies from quickly replenishing depleted stock

Geographic concentration of manufacturing creating regional supply imbalances

Strength-specific demand spikes (particularly 10 mg tablets)

Clinical Implications: When a Patient Cannot Fill Their Enalapril Prescription

Supply disruptions for enalapril carry material clinical risk for certain patient populations:

Heart failure patients: Enalapril is a guideline-recommended RAAS inhibitor for HFrEF. Abrupt discontinuation can worsen heart failure symptoms, increase neurohormonal activation, and elevate rehospitalization risk.

Hypertension patients: Abrupt ACE inhibitor discontinuation can cause rebound hypertension, increasing stroke and MI risk.

LV dysfunction patients: Enalapril is specifically indicated to delay progression to symptomatic heart failure in asymptomatic patients with EF ≤35%. Gaps in therapy may reduce the protective effect.

Therapeutic Substitution Options

When enalapril is unavailable, the following substitutions are clinically reasonable (patient-specific factors apply):

Lisinopril — same ACE inhibitor class; FDA-approved for hypertension, HF, and post-MI; widely available; once-daily dosing. Enalapril 10 mg twice daily is roughly equivalent to lisinopril 20-40 mg once daily.

Ramipril — ACE inhibitor with proven mortality benefit in post-MI and high-CV-risk patients (HOPE trial); once or twice daily; available as generic.

Losartan or Valsartan (ARBs) — appropriate for patients with ACE inhibitor-induced cough or angioedema history. Do not combine with ACE inhibitor (dual RAS blockade contraindicated).

Sacubitril/Valsartan (Entresto) — for HFrEF patients, this ARNI may be considered per guideline preference, but requires a 36-hour washout from all ACE inhibitors before initiation to minimize angioedema risk. Generic sacubitril/valsartan became available in mid-2025.

37,599+ patients found their medications in stock

37K+

Find Enalapril In Stock Today →

Prescribing Strategies to Help Your Patients

Write 90-day supplies whenever possible to reduce supply chain touchpoints.

Prescribe by generic name (enalapril maleate) to allow pharmacies to dispense whichever manufacturer's product is available.

Have a documented alternative ACE inhibitor or ARB on file for patients most at risk from supply disruptions.

Advise patients to use medfinder if they cannot find enalapril at their usual pharmacy — it calls pharmacies nearby and finds in-stock locations, reducing adherence gaps.

Proactively counsel all enalapril patients — especially HFrEF patients — never to stop their medication without calling your office first.

Resources for Providers

FDA Drug Shortage Database — check current shortage status for enalaprilat IV and any formulation changes

ASHP Drug Shortage Resource Center — clinical guidance and therapeutic alternatives during shortages

medfinder for Providers — helps your patients locate enalapril in stock near them without calling every pharmacy

Skip the calls, skip the stress.

Find Enalapril In Stock Today →

50K+

Medications
Found

99%

Success
Rate

6+

Hours saved
on average

Summary for Prescribers

Enalapril oral tablets are not in a formal national shortage in 2026, but pharmacy-level stock-outs remain a concern. The clinical stakes are highest for HFrEF and asymptomatic LV dysfunction patients. Proactive strategies — 90-day prescriptions, documented alternatives, and patient education about not stopping medication — can substantially reduce the clinical impact of supply disruptions.